SCHEDULE: Federated Hermes Discloses Ovid Therapeutics Stake

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 4.15% of Ovid Therapeutics Inc. common stock as of June 30, 2026.

Summary

• Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, have filed an amendment to their Schedule 13G filing.
• This filing pertains to their beneficial ownership of Ovid Therapeutics Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially own 7,737,166 shares of Ovid Therapeutics Inc. common stock.
• This represents 4.15% of the total class of securities.
• Federated Hermes, Inc. is identified as a parent holding company, and the other individuals are trustees of the Voting Shares Irrevocable Trust, which holds all voting stock of Federated Hermes, Inc.
• The filing clarifies that this is not an admission of beneficial ownership for all securities held by managed funds, and beneficial ownership of securities held by managed funds is expressly disclaimed.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a standard disclosure of ownership and does not provide new operational or financial information about Ovid Therapeutics.

Positives

• Federated Hermes, Inc. and associated entities have disclosed their significant stake in Ovid Therapeutics Inc., providing transparency to the market.
• The filing confirms a substantial beneficial ownership of 7,737,166 shares, representing 4.15% of the common stock.

Negatives

• The filing includes a disclaimer of beneficial ownership for securities held by managed funds, which could indicate a complex ownership structure or a desire to limit liability.

Risks

• The disclaimer regarding beneficial ownership of securities held by managed funds could imply potential future divestment or a lack of direct control over those specific holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Ovid Therapeutics Inc.'s future performance. It is a disclosure of current beneficial ownership.

Management Comments

• In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. This filing indicates a significant passive investment by Federated Hermes in Ovid Therapeutics, a biotechnology company.

Stakeholder Impact

• Shareholders of Ovid Therapeutics Inc. are informed of a significant institutional investor's holdings, which can influence market perception and potential future trading activity.
• The disclaimer regarding beneficial ownership may raise questions among sophisticated investors about the precise nature of control and intent behind the investment.

Next Steps

• Continue to monitor future SEC filings from Federated Hermes, Inc. and Ovid Therapeutics Inc. for any changes in ownership or corporate actions.

Key Dates

Keywords

Ovid Therapeutics Inc., Schedule 13G, Federated Hermes, Inc., Beneficial Ownership, Common Stock, Investment Company, Parent Holding Company, Voting Shares Irrevocable Trust, SEC Filing